keyword
MENU ▼
Read by QxMD icon Read
search

Decompensated cirrhosis

keyword
https://www.readbyqxmd.com/read/28811901/perioperative-safety-analysis-of-transcatheter-arterial-chemoembolization-for-hepatocellular-carcinoma-patients-with-preprocedural-leukopenia-or-thrombocytopenia
#1
Lin Zhou, Lin-Zhi Zhang, Jing-Yan Wang, Yong-Wu Li, Hai-Dong Hu, Xiao-Ming Peng, Yun Zhao, Xi-Ming Wang, Hui Xie, Chun-Zi Liu, Hua-Ming Wang
Patients with hepatocellular carcinoma (HCC) exhibit a high incidence of concomitant cirrhosis with leukopenia and/or thrombocytopenia. In the present study, perioperative changes in the white blood cell (WBC) and platelet (PLT) counts and associated complications were investigated to assess the safety of transcatheter arterial chemoembolization (TACE) for HCC patients with preprocedural leukopenia or thrombocytopenia. The records of 1,461 HCC patients who received TACE between January 2012 and December 2013 were retrospectively reviewed...
September 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28811718/chronic-liver-failure-consortium-acute-on-chronic-liver-failure-and-acute-decompensation-scores-predict-mortality-in-brazilian-cirrhotic-patients
#2
Rafael Veiga Picon, Franciele Sabadin Bertol, Cristiane Valle Tovo, Ângelo Zambam de Mattos
AIM: To validate prognostic scores for acute decompensation of cirrhosis and acute-on-chronic liver failure in Brazilian patients. METHODS: This is a prospective cohort study designed to assess the prognostic performance of the chronic liver failure-consortium (CLIF-C) acute decompensation score (CLIF-C AD) and CLIF-C acute-on-chronic liver failure score (CLIF-C ACLF), regarding 28-d and 90-d mortality, as well as to compare them to other prognostic models, such as Model for End-Stage Liver Disease (MELD), MELD Sodium (MELD-Na), Child-Pugh (CP) score, and the CLIF-C Organ Failure score (CLIF-C OF)...
July 28, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28809733/circulating-levels-of-pentraxin-3-ptx3-in-patients-with-liver-cirrhosis
#3
Janaína L Narciso-Schiavon, Jéssica G Pereira, Telma Erotides Silva, Emília T O Bansho, Edelton F Morato, José T Pinheiro, Letícia Muraro-Wildner, Maria Luiza Bazzo, Esther Buzaglo Dantas-Corrêa, Leonardo L Schiavon
BACKGROUND: Despite the circulating levels of PTX3 were related to the severity of various diseases, there are no studies investigating its role in patients with liver cirrhosis. We aimed to study PTX3 levels in patients with liver cirrhosis. MATERIAL AND METHODS: A prospective cohort study included 130 patients hospitalized for acute decompensation of liver cirrhosis, 29 stable cirrhotic outpatients and 32 healthy controls evaluated in a tertiary hospital in Southern Brasil...
August 8, 2017: Annals of Hepatology
https://www.readbyqxmd.com/read/28804006/vitamin-d-deficiency-is-a-risk-factor-for-infections-in-patients-affected-by-hcv-related-liver-cirrhosis
#4
Antonio Riccardo Buonomo, Emanuela Zappulo, Riccardo Scotto, Biagio Pinchera, Giuseppe Perruolo, Pietro Formisano, Guglielmo Borgia, Ivan Gentile
OBJECTIVES: To evaluate the prevalence of vitamin D deficiency and its impact on infections in HCV-related liver cirrhosis. METHODS: We enrolled 291 patients affected by HCV-related liver cirrhosis. Serum vitamin D levels were dosed at enrolment. The presence of infection was assessed at baseline and during follow-up based on physical examination and laboratory analyses. RESULTS: Vitamin D deficiency (<20ng/mL) was diagnosed in 68.3% of patients, and a total of 102 infections were detected...
August 10, 2017: International Journal of Infectious Diseases: IJID
https://www.readbyqxmd.com/read/28803953/fibrosis-stage-but-not-nash-predicts-mortality-and-time-to-development-of-severe-liver-disease-in-biopsy-proven-nafld
#5
Hannes Hagström, Patrik Nasr, Mattias Ekstedt, Ulf Hammar, Per Stål, Rolf Hultcrantz, Stergios Kechagias
BACKGROUND AND AIMS: Non-alcoholic fatty liver disease (NAFLD) is highly common in the general population, but identifying patients with increased risk for mortality and liver-specific morbidity remains a challenge. Non-alcoholic steatohepatitis (NASH) is thought to enhance this risk; therefore, resolution of NASH is a major endpoint in current pharmacologic studies. METHODS: We conducted a retrospective cohort study of 646 biopsy-proven NAFLD patients. Each case was matched for age, sex and municipality to ten controls...
August 10, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/28802062/modeling-the-epidemic-of-nonalcoholic-fatty-liver-disease-demonstrates-an-exponential-increase-in-burden-of-disease
#6
Chris Estes, Homie Razavi, Rohit Loomba, Zobair Younossi, Arun J Sanyal
BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) and resulting nonalcoholic steatohepatitis (NASH) are highly prevalent in the US, where they are a growing cause of cirrhosis and hepatocellular carcinoma (HCC), and increasingly, an indicator for liver transplantation. METHODS: A Markov model was used to forecast NAFLD disease progression. Incidence of NAFLD was based on historical and projected changes in adult prevalence of obesity and type 2 diabetes mellitus (DM)...
August 12, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/28800720/jc-virus-related-progressive-multifocal-leukoencephalopathy-after-living-donor-liver-transplant-a-rare-case
#7
Archana Rastogi, Natasha Gulati, Chhagan Bihari, Ashok Chaudhary, Kalpana Bansal, Shridhar Sasturkar, Shalini Thapar, Viniyendra Pamecha
Progressive multifocal leukoencephalopathy caused by polyoma JC virus is a rare and severe demyelinating disease of the central nervous system. It occurs in immunocompromised patients and is scarcely reported in liver transplant recipients. Brain biopsy demonstrating demyelination with presence of foamy macrophages, relative preservation of axons, astrogliosis, and typical polyomavirus inclusions in the enlarged oligodendroglial nuclei is essential for diagnosis. Here, we report a case of JC virus-associated progressive multifocal leukoencephalopathy in a living-donor liver transplant recipient who was transplanted for hepatitis C virus-related decompensated cirrhosis...
August 12, 2017: Experimental and Clinical Transplantation
https://www.readbyqxmd.com/read/28800033/predictors-of-early-discontinuation-of-interferon-free-direct-antiviral-agents-in-patients-with-hepatitis-c-virus-and-advanced-liver-fibrosis-results-of-a-real-life-cohort
#8
Noelle Miotto, Leandro C Mendes, Letícia P Zanaga, Eduardo S L Goncales, Maria S K Lazarini, Marcelo N Pedro, Fernando L Gonçales, Raquel S B Stucchi, Aline G Vigani
AIM: The aim of this study was to determine risk factors for premature treatment discontinuation among patients with hepatitis C and advanced fibrosis with advanced fibrosis treated with interferon (IFN)-free direct antiviral agents (DAA)-based therapy. PATIENTS AND METHODS: We included all patients with chronic hepatitis C virus infection and advanced liver fibrosis in whom treatment was initiated with IFN-free DAA therapy at a university hospital from December 2015 through June 2016...
August 10, 2017: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28783247/bacterial-translocation-and-clinical-progression-of-hcv-related-cirrhosis-in-hiv-infected-patients
#9
Nicolás Merchante, Teresa Aldámiz-Echevarría, Mónica García-Álvarez, Antonio Rivero-Juárez, Juan Macías, Pilar Miralles, María A Jiménez-Sousa, María Mancebo, Leire Pérez-Latorre, Daniel Pineda-Tenor, Juan Berenguer, Salvador Resino, Juan A Pineda
The aim of the study was to evaluate if bacterial translocation (BT) predicts the clinical outcome in HIV/HCV-coinfected patients with compensated cirrhosis. Acohort of 282 HIV/HCV-coinfected patients with cirrhosis and no previous liver decompensation (LD) was recuited. Serum levels of the DNA sequences encoding the well-conserved 16S rRNA subunit (16S rDNA), the lipopolysaccharide (LPS) and soluble CD14 (sCD14) at diagnosis of cirrhosis were measured. Primary end-point was the emergence of the first LD and/or death of any cause...
August 7, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28782338/sofosbuvir-for-the-treatment-of-hepatitis-c-genotype-3-infected-patients-in-pakistan
#10
Tayyab Saeed Akhter, Muhammad Umar, Hammama-Tul-Bushra Khaar, Faiza Aslam, Gul Nisar, Aqsa Naseer, Sadia Ahmad, Muhammad Osama
Background: This study was conducted to determine the viral responses of patients with chronic infection of Hepatitis C virus treated with sofubuvir. Methods: This Quasi experimental study was conducted at Centre for Liver and Digestive Diseases, Holy Family Hospital, Rawalpindi from September 2014 to September 2016. 502 patients with HCV genotype 3 including treatment naive, non-responders or relapsers to previous interferon based therapy along with patients having decompensated cirrhosis (child class B or C) were included in the study...
October 2016: Journal of Ayub Medical College, Abbottabad: JAMC
https://www.readbyqxmd.com/read/28774413/management-of-hepatitis-b-in-special-populations
#11
REVIEW
Kali Zhou, Norah Terrault
Special populations infected with chronic HBV include those with decompensated cirrhosis, coinfections (HIV, HCV, HDV), hemodialysis and renal failure, immunosuppressed including transplant patients, children and women in pregnancy. These populations differ in their natural history and risk for liver-related complications, the indications for anti-HBV therapy as well as the recommendations regarding the HBV drugs used, duration of therapy and anticipated endpoints. Reflecting the special populations with substantive changes in management in recent years, this review focuses on HBV-HIV coinfected patients, immunosuppressed patients at risk for reactivation, liver transplant recipients and pregnant women...
June 2017: Best Practice & Research. Clinical Gastroenterology
https://www.readbyqxmd.com/read/28768371/minimal-hepatic-encephalopathy-identifies-patients-at-risk-of-faster-cirrhosis-progression
#12
Javier Ampuero, Carmina Montoliú, Macarena Simón-Talero, Virginia Aguilera, Raquel Millán, Celina Márquez, Rodrigo Jover, María Carmen Rico, Carmen Sendra, Miguel Ángel Serra, Manuel Romero-Gómez
BACKGROUND &AIM: Minimal hepatic encephalopathy (MHE) predicts poor prognosis and could reflect an advanced liver disease. We aimed to assess whether MHE could be a surrogate marker of a further liver disease. METHODS: Prospective multicenter study including 320 cirrhotic patients, followed for up to 5 years, which were classified at baseline in: compensated cirrhosis without (stage 1) and with varices (stage 2), one decompensating event (stage 3), any second decompensating event (stage 4)...
August 2, 2017: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28765688/impact-of-hepatitis-c-oral-therapy-in-portal-hypertension
#13
EDITORIAL
Diogo Libânio, Rui Tato Marinho
Chronic hepatitis C is a leading cause of morbidity and mortality, mainly related to fibrosis/cirrhosis and portal hypertension. Direct antiviral agents are highly effective and safe and can now cure > 90% of the patients. Sustained viral response (SVR) after interferon-based regimens has been associated with improvement in liver function, fibrosis and portal hypertension in a significant proportion of patients, although a point of no return seems to exist from which viral elimination is no longer capable of preventing portal hypertension progression and liver decompensation...
July 14, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28763837/-the-treatment-of-early-stage-liver-cancer
#14
X D Zhu, H C Sun
Although the diagnostic rate of early-stage liver cancer is low, only these patients have a chance of radical treatment, and thus related treatment modalities deserve attention. Surgical resection is the preferred choice for the treatment of early-stage liver cancer. For patients with high selectivity, local treatment including radiofrequency ablation can achieve satisfactory outcomes. Liver transplantation is the preferred choice for patients with decompensated liver cirrhosis. Early-stage liver cancer has a high postoperative recurrence rate, and the research and development of postoperative adjuvant therapy should be taken seriously...
May 20, 2017: Zhonghua Gan Zang Bing za Zhi, Zhonghua Ganzangbing Zazhi, Chinese Journal of Hepatology
https://www.readbyqxmd.com/read/28759808/platelet-to-lymphocyte-ratio-plr-and-neutrophil-to-lymphocyte-ratio-nlr-are-associated-with-chronic-hepatitis-b-virus-hbv-infection
#15
Zhidan Zhao, Jianhua Liu, Jiaxin Wang, Tinyan Xie, Qiuhuan Zhang, Sisi Feng, Hui Deng, Baiyun Zhong
OBJECTIVE: This retrospective study aimed to investigate the associations between the platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR) and disease severity in patients with chronic HBV infection-related liver disease (CHB). METHODS: Patients with CHB were retrospectively identified. Clinical data for 172 HBV-infected patients and 40 healthy controls were collected from the electronic patient medical record system database of our hospital...
July 28, 2017: International Immunopharmacology
https://www.readbyqxmd.com/read/28752768/effects-of-antiviral-therapy-in-patients-with-chronic-hepatitis-b-and-cirrhosis
#16
Masako Okada, Masaru Enomoto, Norifumi Kawada, Mindie H Nguyen
Hepatitis B virus (HBV) infection is the major cause of cirrhosis worldwide. The ultimate goal of current antiviral treatments for chronic hepatitis B (nucleos(t)ide analogs and interferon-α) is to prevent the development of end-stage liver diseases. Areas covered: We present a review of the current literature on antiviral therapy in patients with chronic hepatitis B and cirrhosis. Medline search was performed to identify relevant literature from 1993 through January of 2017. Expert commentary: One randomized controlled trial and a number of observational studies have shown that nucleos(t)ide analogs can decrease the incidence of hepatocellular carcinoma (HCC) in chronic hepatitis B patients with advanced fibrosis...
July 28, 2017: Expert Review of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28751810/effectiveness-of-tolvaptan-monotherapy-and-low-dose-furosemide-tolvaptan-combination-therapy-for-hepatoprotection-and-diuresis-in-a-rat-cirrhotic-model
#17
Norikazu Tanabe, Taro Takami, Koichi Fujisawa, Toshihiko Matsumoto, Naoki Yamamoto, Isao Sakaida
Spironolactone and furosemide, which are used to treat ascites associated with decompensated cirrhosis, are ineffective in treating refractory ascites. Hence, combination therapy with tolvaptan, a vasopressin V2 receptor antagonist, has been approved in Japan. Tolvaptan monotherapy and combination therapy with furosemide inhibit fibrosis in cardiac remodeling; hence, we examined these therapies in a rat cirrhotic model, including their usefulness in inhibiting hepatic fibrosis. In the present study, we used a model of hepatic fibrosis induced by a choline-deficient l-amino-acid-defined diet + diethylnitrosamine...
July 2017: Journal of Clinical Biochemistry and Nutrition
https://www.readbyqxmd.com/read/28744162/validity-of-an-automated-algorithm-using-diagnosis-and-procedure-codes-to-identify-decompensated-cirrhosis-using-electronic-health-records
#18
Mei Lu, Wadih Chacra, David Rabin, Loralee B Rupp, Sheri Trudeau, Jia Li, Stuart C Gordon
Viral hepatitis-induced cirrhosis can progress to decompensated cirrhosis. Clinical decompensation represents a milestone event for the patient with cirrhosis, yet there remains uncertainty regarding precisely how to define this important phenomenon. With the development of broader treatment options for cirrhotic hepatitis patients, efficient identification of liver status before evolving to decompensated cirrhosis could be life-saving, but research on the topic has been limited by inconsistencies across studies, populations, and case-confirmation methods...
2017: Clinical Epidemiology
https://www.readbyqxmd.com/read/28738457/-survey-of-economic-burden-of-hepatitis-b-related-diseases-in-12-areas-in-china
#19
Q S Ma, S Liang, H W Xiao, S X Zhang, G H Zhuang, Y H Zou, H Z Tan, J C Liu, Y H Zhang, A Q Xu, L Zhang, X X Feng, D S Hu, F Z Wang, F Q Cui, X F Liang
Objective: Less surveys on the economic burden of hepatitis B (HB)-related diseases have been conducted in China, so the socioeconomic harm caused by the diseases is not clear and the key parameters for economic evaluation of hepatitis B prevention and treatment are lacking. This study aimed to analyze the direct, indirect and intangible expenditures of hospitalized patients with HB-related diseases during hospitalization and during a year in different areas of China. Methods: The hospitals for infectious diseases and the large general hospitals in 12 areas in China were selected in the study...
July 10, 2017: Zhonghua Liu Xing Bing Xue za Zhi, Zhonghua Liuxingbingxue Zazhi
https://www.readbyqxmd.com/read/28738454/-development-of-markov-models-for-economics-evaluation-of-strategies-on-hepatitis-b-vaccination-and-population-based-antiviral-treatment-in-china
#20
P C Yang, S X Zhang, P P Sun, Y L Cai, Y Lin, Y H Zou
Objective: To construct the Markov models to reflect the reality of prevention and treatment interventions against hepatitis B virus (HBV) infection, simulate the natural history of HBV infection in different age groups and provide evidence for the economics evaluations of hepatitis B vaccination and population-based antiviral treatment in China. Methods: According to the theory and techniques of Markov chain, the Markov models of Chinese HBV epidemic were developed based on the national data and related literature both at home and abroad, including the settings of Markov model states, allowable transitions and initial and transition probabilities...
July 10, 2017: Zhonghua Liu Xing Bing Xue za Zhi, Zhonghua Liuxingbingxue Zazhi
keyword
keyword
72152
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"